Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257166 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
NCT00257166 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 238 participants.
The verdict
NCT00257166, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
Interventions
- DRUG Ziprasidone oral capsules
- DRUG placebo oral capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257166
The ClinicalTrials.gov registry entry for NCT00257166 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ziprasidone oral capsules is the first listed.
NCT00257166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257166 about?
NCT00257166 is a clinical study titled "Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)". The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
What is the current status of trial NCT00257166?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2006-01. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00257166?
The interventions under investigation include: Ziprasidone oral capsules (DRUG), placebo oral capsules (DRUG).
Who is sponsoring clinical trial NCT00257166?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.